Wendy Tzou
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 86 | 2026 | 351 | 16.720 |
Why?
| | Tachycardia, Ventricular | 47 | 2025 | 177 | 11.520 |
Why?
| | Atrial Fibrillation | 29 | 2026 | 519 | 6.430 |
Why?
| | Cardiomyopathies | 18 | 2025 | 335 | 3.620 |
Why?
| | Arrhythmias, Cardiac | 23 | 2024 | 352 | 2.710 |
Why?
| | Electrophysiologic Techniques, Cardiac | 19 | 2024 | 83 | 2.540 |
Why?
| | Cicatrix | 6 | 2022 | 72 | 2.060 |
Why?
| | Transcatheter Aortic Valve Replacement | 5 | 2023 | 142 | 1.980 |
Why?
| | Ventricular Premature Complexes | 9 | 2025 | 36 | 1.920 |
Why?
| | Defibrillators, Implantable | 16 | 2025 | 315 | 1.810 |
Why?
| | Electrocardiography | 21 | 2025 | 639 | 1.680 |
Why?
| | Heart Ventricles | 13 | 2025 | 754 | 1.680 |
Why?
| | Pacemaker, Artificial | 6 | 2025 | 122 | 1.650 |
Why?
| | Heart Diseases | 6 | 2023 | 343 | 1.540 |
Why?
| | Cardiac Electrophysiology | 11 | 2024 | 21 | 1.400 |
Why?
| | Heart Block | 4 | 2024 | 40 | 1.350 |
Why?
| | Pericardium | 9 | 2021 | 61 | 1.320 |
Why?
| | Atrioventricular Block | 2 | 2021 | 45 | 1.240 |
Why?
| | Aortic Valve Stenosis | 4 | 2023 | 247 | 1.210 |
Why?
| | Amiodarone | 2 | 2021 | 31 | 1.190 |
Why?
| | Cardiac Pacing, Artificial | 5 | 2023 | 82 | 1.170 |
Why?
| | Pulmonary Veins | 3 | 2019 | 105 | 1.150 |
Why?
| | Heart Failure | 7 | 2024 | 2181 | 1.040 |
Why?
| | Death, Sudden, Cardiac | 6 | 2025 | 196 | 1.010 |
Why?
| | Heart Conduction System | 11 | 2024 | 93 | 1.000 |
Why?
| | Atrial Appendage | 3 | 2022 | 23 | 0.960 |
Why?
| | Treatment Outcome | 43 | 2026 | 11581 | 0.930 |
Why?
| | Humans | 130 | 2026 | 144856 | 0.910 |
Why?
| | Myocardium | 12 | 2023 | 949 | 0.910 |
Why?
| | Recurrence | 18 | 2026 | 1125 | 0.880 |
Why?
| | Echocardiography | 7 | 2025 | 642 | 0.860 |
Why?
| | Electric Countershock | 6 | 2023 | 116 | 0.820 |
Why?
| | Muscular Dystrophies | 1 | 2023 | 32 | 0.790 |
Why?
| | Anti-Arrhythmia Agents | 9 | 2024 | 137 | 0.790 |
Why?
| | Neuromuscular Diseases | 2 | 2024 | 145 | 0.790 |
Why?
| | Electrocardiography, Ambulatory | 3 | 2019 | 62 | 0.760 |
Why?
| | Endocardium | 7 | 2022 | 31 | 0.760 |
Why?
| | Myocarditis | 1 | 2023 | 102 | 0.730 |
Why?
| | Electrodes | 6 | 2022 | 116 | 0.730 |
Why?
| | Postoperative Complications | 9 | 2026 | 2934 | 0.730 |
Why?
| | Pericardial Effusion | 2 | 2022 | 20 | 0.710 |
Why?
| | Carotid Arteries | 4 | 2006 | 203 | 0.700 |
Why?
| | Heart Atria | 7 | 2025 | 143 | 0.690 |
Why?
| | Atrial Flutter | 4 | 2025 | 44 | 0.680 |
Why?
| | Surgery, Computer-Assisted | 1 | 2021 | 84 | 0.630 |
Why?
| | Esophagus | 3 | 2023 | 259 | 0.630 |
Why?
| | Ablation Techniques | 2 | 2019 | 36 | 0.610 |
Why?
| | Cardiology | 5 | 2020 | 292 | 0.610 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2022 | 358 | 0.590 |
Why?
| | Consensus | 9 | 2020 | 482 | 0.590 |
Why?
| | Aged | 45 | 2026 | 25822 | 0.570 |
Why?
| | Heart Rate | 7 | 2025 | 847 | 0.560 |
Why?
| | Risk Factors | 23 | 2026 | 10672 | 0.560 |
Why?
| | Middle Aged | 55 | 2026 | 35939 | 0.560 |
Why?
| | Tunica Intima | 4 | 2008 | 76 | 0.550 |
Why?
| | Action Potentials | 8 | 2025 | 509 | 0.550 |
Why?
| | Epicardial Mapping | 5 | 2022 | 5 | 0.490 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2017 | 45 | 0.480 |
Why?
| | Male | 66 | 2026 | 72189 | 0.480 |
Why?
| | Registries | 10 | 2026 | 2253 | 0.470 |
Why?
| | Tachycardia, Supraventricular | 2 | 2021 | 45 | 0.470 |
Why?
| | Therapeutic Irrigation | 4 | 2020 | 70 | 0.460 |
Why?
| | Risk Assessment | 15 | 2025 | 3580 | 0.460 |
Why?
| | Cardiac Catheters | 4 | 2020 | 16 | 0.460 |
Why?
| | Bradycardia | 3 | 2025 | 57 | 0.460 |
Why?
| | Venous Thrombosis | 1 | 2017 | 194 | 0.440 |
Why?
| | Syncope, Vasovagal | 2 | 2025 | 6 | 0.440 |
Why?
| | Female | 64 | 2026 | 78217 | 0.440 |
Why?
| | Sarcoidosis | 3 | 2024 | 160 | 0.420 |
Why?
| | Catheters | 4 | 2022 | 75 | 0.420 |
Why?
| | Body Temperature | 3 | 2015 | 224 | 0.420 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1171 | 0.420 |
Why?
| | Multimodal Imaging | 3 | 2019 | 122 | 0.410 |
Why?
| | Time Factors | 14 | 2025 | 7107 | 0.400 |
Why?
| | Bundle-Branch Block | 3 | 2023 | 32 | 0.390 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2013 | 32 | 0.390 |
Why?
| | Societies, Medical | 5 | 2020 | 865 | 0.390 |
Why?
| | Aortic Valve | 4 | 2023 | 360 | 0.390 |
Why?
| | Retrospective Studies | 29 | 2026 | 16937 | 0.370 |
Why?
| | Heart | 6 | 2022 | 635 | 0.360 |
Why?
| | Atrioventricular Node | 2 | 2021 | 15 | 0.350 |
Why?
| | Swine | 7 | 2023 | 843 | 0.340 |
Why?
| | Predictive Value of Tests | 8 | 2019 | 2103 | 0.340 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 2 | 2021 | 28 | 0.330 |
Why?
| | Stroke Volume | 9 | 2025 | 617 | 0.320 |
Why?
| | Cattle | 12 | 2020 | 1006 | 0.320 |
Why?
| | Heart Valve Prosthesis | 2 | 2025 | 125 | 0.320 |
Why?
| | Incidence | 7 | 2021 | 2865 | 0.320 |
Why?
| | Tunica Media | 3 | 2008 | 36 | 0.310 |
Why?
| | Carotid Artery Diseases | 2 | 2008 | 68 | 0.310 |
Why?
| | Ventricular Fibrillation | 2 | 2025 | 64 | 0.310 |
Why?
| | Anticoagulants | 4 | 2025 | 721 | 0.300 |
Why?
| | Cardiac Catheterization | 2 | 2022 | 531 | 0.300 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2025 | 374 | 0.300 |
Why?
| | Ventricular Function, Left | 5 | 2021 | 522 | 0.290 |
Why?
| | Follow-Up Studies | 14 | 2025 | 5350 | 0.290 |
Why?
| | Ultrasonography | 3 | 2008 | 766 | 0.280 |
Why?
| | Tricuspid Valve | 2 | 2025 | 39 | 0.270 |
Why?
| | Survival Rate | 5 | 2019 | 2051 | 0.260 |
Why?
| | Decision Support Techniques | 2 | 2022 | 447 | 0.250 |
Why?
| | Body Surface Potential Mapping | 5 | 2019 | 8 | 0.250 |
Why?
| | Cardiac Surgical Procedures | 3 | 2021 | 599 | 0.250 |
Why?
| | Hypercapnia | 1 | 2007 | 53 | 0.250 |
Why?
| | Adult | 28 | 2025 | 40438 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2024 | 1701 | 0.250 |
Why?
| | Reoperation | 3 | 2019 | 614 | 0.250 |
Why?
| | Coronary Circulation | 1 | 2007 | 135 | 0.250 |
Why?
| | Genetic Testing | 1 | 2009 | 479 | 0.240 |
Why?
| | Elective Surgical Procedures | 2 | 2026 | 198 | 0.240 |
Why?
| | Cardiac Imaging Techniques | 2 | 2019 | 24 | 0.230 |
Why?
| | Multicenter Studies as Topic | 3 | 2024 | 399 | 0.230 |
Why?
| | Arterial Switch Operation | 1 | 2025 | 14 | 0.230 |
Why?
| | Thromboembolism | 2 | 2025 | 125 | 0.230 |
Why?
| | Punctures | 1 | 2025 | 39 | 0.230 |
Why?
| | Blood Flow Velocity | 1 | 2007 | 414 | 0.230 |
Why?
| | Arteriosclerosis | 1 | 2005 | 83 | 0.230 |
Why?
| | Transposition of Great Vessels | 1 | 2025 | 36 | 0.230 |
Why?
| | Intracranial Embolism | 1 | 2025 | 34 | 0.230 |
Why?
| | Mitral Valve Prolapse | 1 | 2025 | 9 | 0.220 |
Why?
| | Coronary Vessels | 1 | 2007 | 250 | 0.220 |
Why?
| | Bundle of His | 2 | 2023 | 19 | 0.220 |
Why?
| | United States | 15 | 2026 | 15723 | 0.220 |
Why?
| | Accessory Atrioventricular Bundle | 2 | 2021 | 13 | 0.210 |
Why?
| | Point-of-Care Systems | 1 | 2006 | 187 | 0.210 |
Why?
| | Hot Temperature | 3 | 2023 | 407 | 0.210 |
Why?
| | Amyloidosis | 1 | 2024 | 45 | 0.210 |
Why?
| | Patient Discharge | 2 | 2025 | 949 | 0.210 |
Why?
| | Reproducibility of Results | 6 | 2019 | 3411 | 0.200 |
Why?
| | Cholesterol | 1 | 2005 | 398 | 0.200 |
Why?
| | Migraine Disorders | 1 | 2025 | 113 | 0.200 |
Why?
| | Liposomes | 2 | 2023 | 251 | 0.190 |
Why?
| | Animals | 19 | 2023 | 38331 | 0.190 |
Why?
| | Rheumatic Diseases | 1 | 2024 | 97 | 0.190 |
Why?
| | Biophysical Phenomena | 2 | 2020 | 68 | 0.190 |
Why?
| | Physicians, Women | 1 | 2024 | 87 | 0.190 |
Why?
| | Carps | 1 | 2022 | 4 | 0.190 |
Why?
| | Encephalitis Virus, Japanese | 1 | 2022 | 2 | 0.190 |
Why?
| | Encephalitis, Japanese | 1 | 2022 | 3 | 0.180 |
Why?
| | Prospective Studies | 7 | 2024 | 7947 | 0.180 |
Why?
| | Temperature | 2 | 2023 | 684 | 0.180 |
Why?
| | Quantum Dots | 1 | 2022 | 39 | 0.180 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 366 | 0.170 |
Why?
| | Philadelphia | 3 | 2019 | 56 | 0.170 |
Why?
| | Pre-Excitation Syndromes | 1 | 2021 | 5 | 0.170 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2021 | 27 | 0.170 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 2 | 2012 | 60 | 0.170 |
Why?
| | Coronary Sinus | 1 | 2020 | 9 | 0.160 |
Why?
| | Skin | 1 | 2005 | 765 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 477 | 0.160 |
Why?
| | Papillary Muscles | 1 | 2019 | 13 | 0.150 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2019 | 22 | 0.150 |
Why?
| | Heart-Assist Devices | 2 | 2023 | 562 | 0.150 |
Why?
| | Prevalence | 5 | 2021 | 2830 | 0.150 |
Why?
| | Aortic Valve Insufficiency | 1 | 2019 | 44 | 0.150 |
Why?
| | Esophageal Fistula | 1 | 2019 | 21 | 0.150 |
Why?
| | Patient Safety | 2 | 2020 | 339 | 0.150 |
Why?
| | Length of Stay | 1 | 2025 | 1321 | 0.150 |
Why?
| | Prognosis | 7 | 2019 | 4253 | 0.150 |
Why?
| | Mitral Valve Insufficiency | 1 | 2019 | 68 | 0.150 |
Why?
| | In Vitro Techniques | 5 | 2020 | 1057 | 0.140 |
Why?
| | Colorado | 3 | 2019 | 4605 | 0.140 |
Why?
| | Heart Septum | 2 | 2025 | 28 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 960 | 0.140 |
Why?
| | Hypertension | 2 | 2017 | 1241 | 0.140 |
Why?
| | Heparin | 1 | 2020 | 250 | 0.140 |
Why?
| | Fibrosis | 2 | 2018 | 548 | 0.140 |
Why?
| | Medicare | 3 | 2022 | 825 | 0.130 |
Why?
| | Materials Testing | 2 | 2016 | 359 | 0.130 |
Why?
| | Environment | 1 | 2018 | 307 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 297 | 0.130 |
Why?
| | Antihypertensive Agents | 2 | 2017 | 500 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 5 | 2025 | 3861 | 0.120 |
Why?
| | Magnets | 1 | 2016 | 21 | 0.120 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 133 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 639 | 0.120 |
Why?
| | Heart Injuries | 1 | 2016 | 41 | 0.120 |
Why?
| | Ferric Compounds | 1 | 2016 | 55 | 0.120 |
Why?
| | Mitral Valve | 2 | 2019 | 92 | 0.120 |
Why?
| | Equipment Design | 4 | 2020 | 534 | 0.120 |
Why?
| | Thermography | 1 | 2015 | 10 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2020 | 657 | 0.110 |
Why?
| | Metal Nanoparticles | 1 | 2016 | 85 | 0.110 |
Why?
| | Odds Ratio | 2 | 2010 | 1058 | 0.110 |
Why?
| | Blood Coagulation | 1 | 2017 | 272 | 0.110 |
Why?
| | Adiposity | 1 | 2020 | 542 | 0.110 |
Why?
| | Hypoxia | 1 | 2022 | 1201 | 0.110 |
Why?
| | Medical Records | 1 | 2015 | 183 | 0.100 |
Why?
| | Nanotubes, Carbon | 1 | 2014 | 48 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2020 | 733 | 0.100 |
Why?
| | Fee-for-Service Plans | 1 | 2014 | 89 | 0.100 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.100 |
Why?
| | Exercise | 1 | 2026 | 2206 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1227 | 0.100 |
Why?
| | Energy Transfer | 1 | 2013 | 49 | 0.100 |
Why?
| | Systole | 2 | 2019 | 173 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2015 | 1086 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 197 | 0.090 |
Why?
| | Hemodynamics | 1 | 2017 | 1117 | 0.090 |
Why?
| | Sinus of Valsalva | 1 | 2012 | 11 | 0.090 |
Why?
| | Cohort Studies | 5 | 2021 | 5898 | 0.090 |
Why?
| | Heart Defects, Congenital | 1 | 2019 | 898 | 0.080 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 278 | 0.080 |
Why?
| | Asia | 2 | 2020 | 68 | 0.080 |
Why?
| | Pressure | 1 | 2011 | 230 | 0.080 |
Why?
| | Latin America | 2 | 2020 | 91 | 0.080 |
Why?
| | Artificial Intelligence | 3 | 2023 | 369 | 0.080 |
Why?
| | Telemetry | 1 | 2010 | 42 | 0.080 |
Why?
| | Pennsylvania | 1 | 2010 | 136 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8185 | 0.080 |
Why?
| | Brugada Syndrome | 1 | 2009 | 14 | 0.080 |
Why?
| | Heart Valve Diseases | 1 | 2011 | 152 | 0.070 |
Why?
| | Genetic Diseases, Inborn | 1 | 2009 | 44 | 0.070 |
Why?
| | Logistic Models | 2 | 2014 | 2098 | 0.070 |
Why?
| | Reference Values | 2 | 2010 | 807 | 0.070 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2011 | 187 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2798 | 0.070 |
Why?
| | Nanoparticles | 1 | 2014 | 520 | 0.070 |
Why?
| | Pharmacogenetics | 1 | 2009 | 173 | 0.070 |
Why?
| | Office Visits | 1 | 2008 | 91 | 0.070 |
Why?
| | Age Factors | 2 | 2018 | 3311 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1987 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2940 | 0.060 |
Why?
| | Blood Gas Analysis | 1 | 2007 | 84 | 0.060 |
Why?
| | Comorbidity | 2 | 2017 | 1640 | 0.060 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 726 | 0.060 |
Why?
| | Miniaturization | 1 | 2006 | 22 | 0.060 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2021 | 153 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 1307 | 0.060 |
Why?
| | Adolescent | 6 | 2025 | 22396 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2411 | 0.060 |
Why?
| | Professional Competence | 1 | 2006 | 97 | 0.060 |
Why?
| | Waist-Hip Ratio | 1 | 2005 | 37 | 0.060 |
Why?
| | Myocardial Contraction | 1 | 2007 | 300 | 0.060 |
Why?
| | Pattern Recognition, Automated | 1 | 2006 | 76 | 0.060 |
Why?
| | Blood Pressure | 2 | 2017 | 1752 | 0.060 |
Why?
| | Pilot Projects | 2 | 2021 | 1873 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 14033 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2024 | 78 | 0.050 |
Why?
| | Carotid Stenosis | 1 | 2006 | 102 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2005 | 126 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2005 | 331 | 0.050 |
Why?
| | Lipoproteins | 1 | 2005 | 163 | 0.050 |
Why?
| | Age Distribution | 1 | 2005 | 396 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 381 | 0.050 |
Why?
| | Cardiologists | 1 | 2024 | 46 | 0.050 |
Why?
| | Anesthesia, Cardiac Procedures | 1 | 2024 | 27 | 0.050 |
Why?
| | ROC Curve | 2 | 2018 | 610 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 286 | 0.050 |
Why?
| | Sternotomy | 1 | 2023 | 25 | 0.050 |
Why?
| | Triglycerides | 1 | 2005 | 517 | 0.050 |
Why?
| | Protamines | 1 | 2023 | 8 | 0.050 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 588 | 0.050 |
Why?
| | Factor Xa | 1 | 2023 | 35 | 0.050 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2016 | 215 | 0.050 |
Why?
| | Linear Models | 1 | 2005 | 860 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 844 | 0.050 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1504 | 0.050 |
Why?
| | Survival Analysis | 2 | 2018 | 1362 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1510 | 0.040 |
Why?
| | Atherosclerosis | 1 | 2006 | 404 | 0.040 |
Why?
| | Career Choice | 1 | 2024 | 237 | 0.040 |
Why?
| | Mentors | 1 | 2024 | 218 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2022 | 124 | 0.040 |
Why?
| | Chlorides | 1 | 2022 | 138 | 0.040 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 517 | 0.040 |
Why?
| | Sex Factors | 2 | 2018 | 2090 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2024 | 600 | 0.040 |
Why?
| | Tachycardia | 1 | 2021 | 57 | 0.040 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 99 | 0.040 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2021 | 32 | 0.040 |
Why?
| | Vagus Nerve | 1 | 2021 | 92 | 0.040 |
Why?
| | Factor Xa Inhibitors | 1 | 2023 | 189 | 0.040 |
Why?
| | Databases, Factual | 2 | 2018 | 1474 | 0.040 |
Why?
| | Doxorubicin | 1 | 2023 | 399 | 0.040 |
Why?
| | Carbon | 1 | 2022 | 203 | 0.040 |
Why?
| | Anesthesia | 1 | 2024 | 247 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 733 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2023 | 269 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2021 | 408 | 0.040 |
Why?
| | Warfarin | 1 | 2020 | 165 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 70 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2023 | 1358 | 0.040 |
Why?
| | Operative Time | 1 | 2020 | 181 | 0.040 |
Why?
| | Europe | 1 | 2020 | 412 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 322 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2008 | 1332 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 553 | 0.040 |
Why?
| | Patient Participation | 1 | 2022 | 436 | 0.040 |
Why?
| | Sus scrofa | 1 | 2018 | 64 | 0.040 |
Why?
| | International Cooperation | 1 | 2019 | 197 | 0.040 |
Why?
| | Decision Trees | 1 | 2018 | 81 | 0.040 |
Why?
| | Necrosis | 1 | 2019 | 245 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2881 | 0.030 |
Why?
| | Electric Impedance | 1 | 2018 | 113 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2018 | 99 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2005 | 2971 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 801 | 0.030 |
Why?
| | Italy | 1 | 2017 | 114 | 0.030 |
Why?
| | Advisory Committees | 1 | 2019 | 208 | 0.030 |
Why?
| | Oxygen | 1 | 2022 | 1003 | 0.030 |
Why?
| | Prosthesis Fitting | 1 | 2016 | 15 | 0.030 |
Why?
| | Body Mass Index | 1 | 2005 | 2448 | 0.030 |
Why?
| | Thermal Conductivity | 1 | 2016 | 5 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 749 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1060 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 394 | 0.030 |
Why?
| | Blood Glucose | 1 | 2005 | 2335 | 0.030 |
Why?
| | Models, Cardiovascular | 1 | 2016 | 197 | 0.030 |
Why?
| | Decision Making | 1 | 2022 | 970 | 0.030 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 24 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1829 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4605 | 0.030 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 48 | 0.030 |
Why?
| | DNA | 1 | 2021 | 1430 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 621 | 0.030 |
Why?
| | Biomarkers | 1 | 2005 | 4279 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 353 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 140 | 0.030 |
Why?
| | Friction | 1 | 2013 | 13 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1685 | 0.030 |
Why?
| | Czech Republic | 1 | 2013 | 4 | 0.030 |
Why?
| | Health Care Costs | 1 | 2017 | 418 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 711 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2012 | 3628 | 0.030 |
Why?
| | Motion | 1 | 2013 | 100 | 0.020 |
Why?
| | Internship and Residency | 1 | 2024 | 1261 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5809 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2017 | 980 | 0.020 |
Why?
| | Surface Properties | 1 | 2013 | 412 | 0.020 |
Why?
| | Veins | 1 | 2012 | 69 | 0.020 |
Why?
| | Algorithms | 2 | 2012 | 1848 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1267 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3165 | 0.020 |
Why?
| | Angiography | 1 | 2011 | 207 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 238 | 0.020 |
Why?
| | Quality Improvement | 1 | 2019 | 1282 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2012 | 312 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3199 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4132 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1309 | 0.020 |
Why?
| | Patient Readmission | 1 | 2014 | 727 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1837 | 0.020 |
Why?
| | Wisconsin | 1 | 2008 | 100 | 0.020 |
Why?
| | Physicians' Offices | 1 | 2006 | 19 | 0.010 |
Why?
| | Observer Variation | 1 | 2006 | 353 | 0.010 |
Why?
| | Image Enhancement | 1 | 2006 | 202 | 0.010 |
Why?
| | Motivation | 1 | 2008 | 607 | 0.010 |
Why?
| | Population Surveillance | 1 | 2006 | 491 | 0.010 |
Why?
| | Health Behavior | 1 | 2008 | 795 | 0.010 |
Why?
| | Family Practice | 1 | 2006 | 416 | 0.010 |
Why?
| | Child | 1 | 2021 | 22620 | 0.010 |
Why?
|
|
Tzou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|